DK1369419T3 - N-phenylarylsulfonamidforbindelse, lægemiddel indeholdende forbindelsen som en aktiv bestanddel, mellemprodukt for forbindelsen og fremgangmåder til fremstilling heraf - Google Patents

N-phenylarylsulfonamidforbindelse, lægemiddel indeholdende forbindelsen som en aktiv bestanddel, mellemprodukt for forbindelsen og fremgangmåder til fremstilling heraf

Info

Publication number
DK1369419T3
DK1369419T3 DK02705096T DK02705096T DK1369419T3 DK 1369419 T3 DK1369419 T3 DK 1369419T3 DK 02705096 T DK02705096 T DK 02705096T DK 02705096 T DK02705096 T DK 02705096T DK 1369419 T3 DK1369419 T3 DK 1369419T3
Authority
DK
Denmark
Prior art keywords
compound
methyl
preparation
methods
phenylarylsulfonamide
Prior art date
Application number
DK02705096T
Other languages
Danish (da)
English (en)
Inventor
Atsushi Naganawa
Kaoru Kobayashi
Takayuki Maruyama
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of DK1369419T3 publication Critical patent/DK1369419T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
DK02705096T 2001-03-12 2002-03-11 N-phenylarylsulfonamidforbindelse, lægemiddel indeholdende forbindelsen som en aktiv bestanddel, mellemprodukt for forbindelsen og fremgangmåder til fremstilling heraf DK1369419T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (fr) 2001-03-12 2002-03-11 Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production

Publications (1)

Publication Number Publication Date
DK1369419T3 true DK1369419T3 (da) 2007-09-24

Family

ID=27346214

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02705096T DK1369419T3 (da) 2001-03-12 2002-03-11 N-phenylarylsulfonamidforbindelse, lægemiddel indeholdende forbindelsen som en aktiv bestanddel, mellemprodukt for forbindelsen og fremgangmåder til fremstilling heraf
DK05109059.5T DK1612208T3 (da) 2001-03-12 2002-03-11 N-phenylarylsulfonamidforbindelse, farmaceutisk sammensætning omfattende forbindelsen som aktiv bestanddel, mellemprodukt til forbindelsen og fremgangsmåde til dens fremstilling

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05109059.5T DK1612208T3 (da) 2001-03-12 2002-03-11 N-phenylarylsulfonamidforbindelse, farmaceutisk sammensætning omfattende forbindelsen som aktiv bestanddel, mellemprodukt til forbindelsen og fremgangsmåde til dens fremstilling

Country Status (24)

Country Link
US (3) US7235667B2 (es)
EP (2) EP1369419B1 (es)
JP (3) JP3555620B2 (es)
KR (1) KR100886854B1 (es)
CN (1) CN1294126C (es)
AT (2) ATE362924T1 (es)
AU (1) AU2002238855B2 (es)
BR (1) BR0208027A (es)
CA (1) CA2439604C (es)
CZ (1) CZ304035B6 (es)
DE (1) DE60220255T2 (es)
DK (2) DK1369419T3 (es)
ES (1) ES2286230T3 (es)
HU (1) HU230056B1 (es)
IL (2) IL157701A0 (es)
MX (1) MXPA03008134A (es)
NO (1) NO329682B1 (es)
NZ (1) NZ528120A (es)
PL (1) PL218750B1 (es)
PT (2) PT1369419E (es)
RU (1) RU2299202C2 (es)
TW (1) TWI317359B (es)
WO (1) WO2002072564A1 (es)
ZA (1) ZA200306884B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022549A1 (ja) * 2002-09-09 2004-03-18 Ono Pharmaceutical Co., Ltd. 4−メチル−1,3−チアゾール−2−イルスルホニルハライドの製造方法
KR101094003B1 (ko) * 2003-01-29 2011-12-15 아스터랜드 유케이 리미티드 Ep4 수용체 길항제
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
EP1642594A1 (en) * 2003-06-27 2006-04-05 Ono Pharmaceutical Co., Ltd. Remedy for urinary tract diseases
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20080033018A1 (en) * 2004-07-05 2008-02-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agents For Overactive Bladder
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
CA2677769C (en) * 2007-02-16 2016-01-19 Ono Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder
US8048898B2 (en) * 2007-08-01 2011-11-01 Taisho Pharmaceutical Co., Ltd Inhibitor of binding of S1P1
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
CA2728511A1 (en) 2008-06-23 2009-12-30 Astellas Pharma Inc. Sulfonamide compounds or salts thereof
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
CN103209960A (zh) * 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
JP6103893B2 (ja) * 2012-11-15 2017-03-29 サントリー食品インターナショナル株式会社 コーヒーオイルの製造方法
WO2015166115A1 (es) * 2014-04-30 2015-11-05 Industrias Peñalver, S.L. Cabezal concéntrico programable para aplicación líquida en tapas multiformato
BR112018009754B1 (pt) * 2015-11-13 2024-01-23 In Therapeutics Composto tendo função bloqueadora de canal de sódio, sua composição farmacêutica e seu uso
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
JPS5748534B2 (es) 1974-03-04 1982-10-16
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
AU4431400A (en) 1999-05-12 2000-12-05 Japan As Represented By President Of National Cancer Center Anticancer agents containing ep1 antagonists as the active ingredient
AU6180600A (en) 1999-07-29 2001-02-19 Ono Pharmaceutical Co. Ltd. Sulfonamide derivatives and remedies for allodynia
EP1369129A4 (en) 2001-03-14 2005-08-03 Ono Pharmaceutical Co ANTIDEPRESSOR REMEDIES CONTAINING AN EP1 ANTAGONIST AS ACTIVE INGREDIENT

Also Published As

Publication number Publication date
US7629369B2 (en) 2009-12-08
ATE362924T1 (de) 2007-06-15
EP1612208A2 (en) 2006-01-04
JP3555620B2 (ja) 2004-08-18
CZ304035B6 (cs) 2013-08-28
JP3741120B2 (ja) 2006-02-01
KR100886854B1 (ko) 2009-03-05
PT1369419E (pt) 2007-08-16
NO329682B1 (no) 2010-11-29
EP1612208B1 (en) 2011-08-31
PT1612208E (pt) 2011-10-12
BR0208027A (pt) 2004-12-28
HUP0400155A2 (hu) 2004-08-30
JP4432051B2 (ja) 2010-03-17
CN1294126C (zh) 2007-01-10
MXPA03008134A (es) 2004-03-10
EP1612208A3 (en) 2006-12-06
ATE522513T1 (de) 2011-09-15
CA2439604A1 (en) 2002-09-19
RU2299202C2 (ru) 2007-05-20
TWI317359B (en) 2009-11-21
KR20030082978A (ko) 2003-10-23
US20050124672A1 (en) 2005-06-09
US20100041708A1 (en) 2010-02-18
DK1612208T3 (da) 2011-12-12
NO20034007D0 (no) 2003-09-10
EP1369419A4 (en) 2005-03-16
AU2002238855B2 (en) 2007-12-06
PL218750B1 (pl) 2015-01-30
IL157701A (en) 2010-06-30
RU2003127677A (ru) 2005-03-27
NZ528120A (en) 2006-05-26
HU230056B1 (hu) 2015-06-29
EP1369419B1 (en) 2007-05-23
ZA200306884B (en) 2005-03-30
CN1509278A (zh) 2004-06-30
CA2439604C (en) 2012-05-01
JP2004149545A (ja) 2004-05-27
PL365100A1 (en) 2004-12-27
WO2002072564A1 (fr) 2002-09-19
NO20034007L (no) 2003-11-12
EP1369419A1 (en) 2003-12-10
DE60220255D1 (de) 2007-07-05
ES2286230T3 (es) 2007-12-01
JPWO2002072564A1 (ja) 2004-07-02
US7235667B2 (en) 2007-06-26
CZ20032452A3 (cs) 2003-11-12
DE60220255T2 (de) 2008-01-17
JP2006028193A (ja) 2006-02-02
IL157701A0 (en) 2004-03-28
US8088802B2 (en) 2012-01-03
US20060030713A1 (en) 2006-02-09
HUP0400155A3 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
DK1369419T3 (da) N-phenylarylsulfonamidforbindelse, lægemiddel indeholdende forbindelsen som en aktiv bestanddel, mellemprodukt for forbindelsen og fremgangmåder til fremstilling heraf
DE60018064D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
NO20032510D0 (no) Organiske forbindelser
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
JP2010530431A5 (es)
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
BR0017025A (pt) Antagonistas do receptor y5 do neuropeptìdeo y de imidazola substituìda
GEP20105082B (en) (biphenyl) carboxylic acids and derivatives thereof
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
ATE404211T1 (de) Xenon als nmda-antogonist zur neuroprotektion
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
MX2007005073A (es) Conjugados con actividad antiinflamtoria.
DK1476470T3 (da) Stivelsesderivater, stivelse-aktivstof-konjugater, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemidler
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
NO20023551L (no) Ibuprofen-inneholdende aktivt middel-preparat
Yu et al. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
NO20043286L (no) Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DK0985414T3 (da) Lægemiddel til behandling af glaukome og iskæmisk retinopati